79345827 - YAVEMBO

Information

  • Trademark
  • 79345827
  • Serial Number
    79345827
  • Registration Number
    7282283
  • Filing Date
    April 27, 2022
    2 years ago
  • Registration Date
    January 23, 2024
    a year ago
  • Transaction Date
    December 10, 2024
    a month ago
  • Status Date
    January 23, 2024
    a year ago
  • Published for Opposition Date
    November 07, 2023
    a year ago
  • Location Date
    January 23, 2024
    a year ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    BULLOFF, TOBY
  • Attorney Name
    Karen Kreider Gaunt
    Law Office Assigned Location Code
    N10
  • Owners
Mark Drawing Code
4
Mark Identification
YAVEMBO
Case File Statements
  • GS0051: Pharmaceutical preparations for injection for the treatment of Polycystic Kidney Disease (PKD); pharmaceutical preparations for injection for the treatment of endocrine diseases and disorders; pharmaceutical preparations for injection for the treatment of tumours; pharmaceutical preparations for injection for the treatment of carcinoid tumours; pharmaceutical preparations comprising peptides for hormonal treatment and tumour treatment; pharmaceutical preparations for injection for the treatment of neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastro-enteropancreatic neuroendocrine tumours; pharmaceutical preparations for injection for the treatment of gastrointestinal diseases and disorders; pharmaceutical preparations for injection for gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of gastrointestinal bleeding disorders; pharmaceutical preparations for injection for the treatment of esophageal bleeding; pharmaceutical preparations for injection for metabolic disorders; pharmaceutical preparations for injection for the treatment of acromegaly; pharmaceutical preparations for injection for the treatment of polycystic liver disease; pharmaceutical preparations for injection for the treatment of respiratory diseases or syndrome; pharmaceutical preparations for injection for the treatment of respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of acute respiratory distress syndrome; pharmaceutical preparations for injection for the treatment of disorders of the autonomic nervous system; pharmaceutical preparations for injection intended to block growth hormone
  • GS0101: Medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of carcinoid tumours; medical devices being infusion and injection devices for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of esophageal bleeding; medical devices being infusion and injection devices for administration of pharmaceuticals for metabolic disorders; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acromegaly; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of polycystic liver disease; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; medical devices being infusion and injection devices for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; medical devices being infusion and injection devices for administration of pharmaceuticals intended to block growth hormone; syringes for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; syringes for administration of pharmaceuticals for the treatment of tumours; syringes for administration of pharmaceuticals for the treatment of carcinoid tumours; syringes for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; syringes for administration of pharmaceuticals for the treatment of neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; syringes for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; syringes for administration of pharmaceuticals for gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; syringes for administration of pharmaceuticals for the treatment of esophageal bleeding; syringes for administration of pharmaceuticals for metabolic disorders; syringes for administration of pharmaceuticals for the treatment of acromegaly; syringes for administration of pharmaceuticals for the treatment of polycystic liver disease; syringes for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; syringes for administration of pharmaceuticals for the treatment of respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; syringes for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; syringes for administration of pharmaceuticals intended to block growth hormone; microneedle dermal pens for administration of pharmaceuticals for the treatment of endocrine diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of carcinoid tumours; microneedle dermal pens for administration of pharmaceuticals comprising peptides for hormonal treatment and tumour treatment; microneedle dermal pens for administration of pharmaceuticals for the treatment of neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastro-enteropancreatic neuroendocrine tumours; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal diseases and disorders; microneedle dermal pens for administration of pharmaceuticals for gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of gastrointestinal bleeding disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of esophageal bleeding; microneedle dermal pens for administration of pharmaceuticals for metabolic disorders; microneedle dermal pens for administration of pharmaceuticals for the treatment of acromegaly; microneedle dermal pens for administration of pharmaceuticals for the treatment of polycystic liver disease; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory diseases or syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of acute respiratory distress syndrome; microneedle dermal pens for administration of pharmaceuticals for the treatment of disorders of the autonomic nervous system; microneedle dermal pens for administration of pharmaceuticals intended to block growth hormone; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; devices for injection of pharmaceutical depots; devices for subcutaneous injection of pharmaceutical depot; devices for parenteral injection of pharmaceutical depot; devices for injection of pharmaceuticals and medical injection fluids; devices for injection of injection depot being pharmaceuticals; medical devices being infusion and injection devices for subcutaneous administration of pharmaceuticals; medical devices being infusion and injection devices for parenteral administration of pharmaceuticals; syringes for subcutaneous administration of pharmaceuticals; syringes for parenteral administration of pharmaceuticals; syringes for injection of pharmaceutical depots; syringes for subcutaneous injection of pharmaceutical depot; syringes for parenteral injection of pharmaceutical depot; syringes for injection of injection fluids; syringes for injection of injection depot; syringes for injections; syringes for medical uses; microneedle dermal pens for subcutaneous administration of pharmaceuticals; microneedle dermal pens for parenteral administration of pharmaceuticals; microneedle dermal pens for injection of pharmaceutical depots; microneedle dermal pens for subcutaneous injection of pharmaceutical depot; microneedle dermal pens for parenteral injection of pharmaceutical depot; microneedle dermal pens for injection of injection fluids; microneedle dermal pens for injection of injection depot; microneedle dermal pens for injections; microneedle dermal pens for medical uses
Case File Event Statements
  • 7/21/2022 - 2 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR
  • 7/22/2022 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 7/26/2022 - 2 years ago
    3 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 2/15/2023 - a year ago
    4 - ASSIGNED TO EXAMINER Type: DOCK
  • 2/16/2023 - a year ago
    5 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 2/17/2023 - a year ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 4/5/2023 - a year ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 4/5/2023 - a year ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 4/25/2023 - a year ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 7/24/2023 - a year ago
    10 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 10/2/2023 - a year ago
    11 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 10/2/2023 - a year ago
    12 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 10/3/2023 - a year ago
    13 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 10/4/2023 - a year ago
    14 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 10/18/2023 - a year ago
    17 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 10/18/2023 - a year ago
    15 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 10/18/2023 - a year ago
    16 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 11/7/2023 - a year ago
    19 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 11/7/2023 - a year ago
    20 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 12/27/2023 - a year ago
    22 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 12/27/2023 - a year ago
    21 - NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB Type: OPNR
  • 1/13/2024 - a year ago
    23 - NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB Type: OPNX
  • 1/23/2024 - a year ago
    24 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 1/23/2024 - a year ago
    25 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 4/23/2024 - 9 months ago
    26 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 4/24/2024 - 9 months ago
    28 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 4/24/2024 - 9 months ago
    27 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 5/13/2024 - 8 months ago
    29 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 12/4/2024 - a month ago
    32 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 12/4/2024 - a month ago
    30 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 12/4/2024 - a month ago
    34 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR
  • 12/4/2024 - a month ago
    33 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 12/4/2024 - a month ago
    35 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 12/4/2024 - a month ago
    31 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 11/6/2023 - a year ago
    18 - NOTIFICATION PROCESSED BY IB Type: GPNX